Life Sciences Archives - EverGlade Consulting

Life Sciences

Medicine capsules global health with geometric pattern digital r

ARPA-H’s Proactive Health Office ISO Amendment 2

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

PROACTIVE HEALTH OFFICE – MISSION OFFICE INNOVATIVE SOLUTIONS OPENING (ISO) – ARPA-H-SOL-24-106 – Amendment 02: June 06, 2025 The Advanced Research Projects Agency for Health (ARPA-H) has recently amended the Proactive Health Office (PHO) Innovative Solutions Opening (ISO). The PHO ISO invites novel and disruptive health innovations aimed at extending health spans and improving health […]

ARPA-H’s Proactive Health Office ISO Amendment 2 Read More »

Doctor holding augmented reality medical-related digital icons

ARPA-H Resilient Systems ISO

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

RESILIENT SYSTEMS OFFICE – MISSION OFFICE INNOVATIVE SOLUTIONS OPENING (ISO) – ARPA-H-SOL-24-103 – Amendment 02: June 06, 2025 The Advanced Research Projects Agency for Health (ARPA-H) has released Amendment 02 of its Innovative Solutions Opening (ISO) under the Resilient Systems Office (RSO), under Solicitation Number ARPA-H-SOL-24-103. a mission-focused solicitation designed to confront systemic challenges across

ARPA-H Resilient Systems ISO Read More »

Digital composite image of scientific experiment and dNA strands

ARPA-H Health Science Futures ISO

Leave a Comment / ARPA-H, Life Sciences / By

Health Science Futures – MISSION OFFICE INNOVATIVE SOLUTIONS OPENING (ISO) ARPA-H-SOL-24-104 – Amendment 02: June 06, 2025 The Advanced Research Projects Agency for Health (ARPA-H) has released Amendment 02 of its Health Science Futures (HSF) Mission Office Innovative Solutions Opening (ISO), under Solicitation Number ARPA-H-SOL-24-104. As part of its mission to catalyze high-risk, high-reward research,

ARPA-H Health Science Futures ISO Read More »

ARPA-H’s Four Mission Offices Sharpen Their Vision with ISO Amendments

ARPA-H’s Four Mission Offices Sharpen Their Vision with ISO Amendments

Leave a Comment / ARPA-H, Life Sciences / By

On June 6, 2025, the Advanced Research Projects Agency for Health (ARPA-H) issued Amendment 02 to its four flagship Innovation Solutions Opening (ISO) solicitations: Health Science Futures (HSF), Proactive Health Office (PHO), Resilient Systems Office (RSO), and Scalable Solutions Office (SSO). These ISOs represent the core operational arms of ARPA-H’s mission to fund transformative, high-risk,

ARPA-H’s Four Mission Offices Sharpen Their Vision with ISO Amendments Read More »

Vaccine Research

Strengthening National Preparedness: BARDA’s FY23 Modernized BAA

Leave a Comment / BARDA, Life Sciences / By

Strengthening National Preparedness: BARDA’s FY23 Modernized BAA BAA-23-100-SOL-00004 – Office of Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) In response to today’s evolving public health landscape, the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services (HHS) within the Administration for Strategic

Strengthening National Preparedness: BARDA’s FY23 Modernized BAA Read More »

Rapid Response Test

BARDA’s DxR2 RPP: Scaling Biothreat Diagnostic Readiness

Leave a Comment / All Posts, BARDA, Life Sciences / By

In a continued effort to bolster national preparedness against emerging biological threats, the Biomedical Advanced Research and Development Authority (BARDA) has released the Phase 2 issue of the “Biothreat Diagnostic Rapid Response” Solicitation (RPP-25-06-DxR2) on May 29, 2025, under its Rapid Response Partnership Vehicle (RRPV). BARDA is seeking to address pressing gaps in diagnostic test

BARDA’s DxR2 RPP: Scaling Biothreat Diagnostic Readiness Read More »

Conveyor belt with blue capsules medicine

ASPR RFI: Public Health Industrial Base Capabilities and Capacities: Essential Medicines

Leave a Comment / ASPR-IBx, Life Sciences / By

ASPR Industrial Base Management and Supply Chain Request for Information (RFI) Understanding the RFI The Public Health Industrial Base Capabilities and Capacities: Essential Medicines RFI is seeking detailed input from domestic manufacturers and industry stakeholders to better understand the current capabilities and constraints in producing a list of 28 designated essential medicines. The scope includes

ASPR RFI: Public Health Industrial Base Capabilities and Capacities: Essential Medicines Read More »

Close-up of Medical Ampoule Production Line at Modern Modern Pharmaceutical Factory. Glass Ampoules are being Filled. Medication Manufacturing Process.

DTRA’s RAVEN RFI Seeks Multivalent Vaccine Innovation

Leave a Comment / All Posts, DTRA, Life Sciences / By

Reimagining the Future of Vaccines: DTRA’s RAVEN RFI The Defense Threat Reduction Agency (DTRA), through its Joint Science and Technology Office (JSTO), has announced a new Request for Information (RFI) under the initiative titled Reimagining Available Vaccines and Envisioning Novelty (RAVEN). This RFI reflects DTRA’s responsibility to prepare the U.S. warfighter for current and emerging

DTRA’s RAVEN RFI Seeks Multivalent Vaccine Innovation Read More »

The White House Initiatives

White House Unveils New Initiatives for Critical Medicines and Biological Research Safety

Leave a Comment / All Posts, ARPA-H, BARDA, Life Sciences / By

Promoting Domestic Production of Critical Medicines The White House is pushing to see more state-of-the-art pharmaceutical manufacturing facilities within the United States to strengthen the supply of essential medicines. On May 5, 2025, the President signed an Executive Order titled “Regulatory Relief to Promote Domestic Production of Critical Medicines.” The goal of this order is

White House Unveils New Initiatives for Critical Medicines and Biological Research Safety Read More »

3D rendering of Lymphocytes

DoD Seeks Host-Directed Therapeutics to Counter Emerging Biological Threats

Leave a Comment / All Posts, JPEO, Life Sciences / By

A New Direction: Host-Directed, Not Pathogen-Specific Unlike traditional antivirals or antibiotics, host-directed therapeutics (HDTs) focus on modulating the patient’s immune response rather than targeting a specific pathogen. This “threat-agnostic” approach is especially promising in an era marked by evolving biological agents and unpredictable infectious threats. The DoD is particularly interested in repurposed FDA-approved therapeutics or

DoD Seeks Host-Directed Therapeutics to Counter Emerging Biological Threats Read More »

Chemical Threat Readiness

Advancing Chemical Threat Readiness: The MCDC’s New Call for Prototypes

Leave a Comment / DTRA, Life Sciences / By

Advancing Chemical Threat Readiness: The MCDC’s New Call for Prototypes April 2025 marks another pivotal moment for U.S. defense readiness in chemical and biological threat detection. Through the Medical CBRN Defense Consortium (MCDC), the Army Contracting Command has issued Solicitation RPP-25-04 seeking Enhanced White Papers for a groundbreaking prototype: the Assay Expansion for Chemical Diagnostic

Advancing Chemical Threat Readiness: The MCDC’s New Call for Prototypes Read More »

immunoassay IEID Lab Solicitation

BARDA’s Central IEID Lab Solicitation: Strengthening Immunoassay Readiness for Pandemic Threats

Leave a Comment / All Posts, BARDA, Life Sciences / By

Why It Matters The rise of highly pathogenic avian influenza (HPAI) strains like H5N1, their spread to livestock, and increasing zoonotic infections in the U.S. has underscored the need for rapid, accurate immune assay infrastructure. BARDA’s RRPV initiative calls for laboratories with existing capabilities to function as a central immunoassay laboratory and perform quality-assured immunoassays

BARDA’s Central IEID Lab Solicitation: Strengthening Immunoassay Readiness for Pandemic Threats Read More »

Scroll to Top